Rami S Komrokji Selected Research

Hematinics

4/2024	CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs).
12/2023	Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
11/2023	Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts.
1/2023	Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
1/2021	Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
1/2020	Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
11/2015	Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
1/2010	Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rami S Komrokji Research Topics

Disease

71	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 04/2024 - 12/2004
28	Neoplasms (Cancer) 05/2024 - 12/2004
24	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/2024 - 03/2011
15	Primary Myelofibrosis (Myelosclerosis) 05/2024 - 11/2010
14	Anemia 01/2023 - 01/2010
13	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 11/2022 - 06/2009
9	Thrombocytopenia (Thrombopenia) 12/2023 - 10/2008
8	Cytopenia 02/2024 - 12/2013
7	Splenomegaly 03/2018 - 12/2013
5	Neutropenia 12/2023 - 12/2004
4	Disease Progression 12/2023 - 12/2013
4	Iron Overload 01/2023 - 09/2014
3	Body Weight (Weight, Body) 01/2023 - 01/2017
3	Nausea 01/2023 - 12/2008
3	Fatigue 01/2023 - 01/2017
3	Thrombosis (Thrombus) 10/2022 - 06/2006
3	Leukemia 11/2021 - 06/2011
3	Febrile Neutropenia 10/2021 - 12/2004
2	Inflammation (Inflammations) 05/2024 - 09/2014
2	Asthenia 01/2023 - 01/2020
2	Headache (Headaches) 01/2023 - 01/2020
2	Leukocytosis (Pleocytosis) 10/2021 - 12/2017
2	Diarrhea 01/2020 - 12/2008
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2016 - 12/2014
2	Polycythemia Vera 01/2016 - 02/2015
2	Chromosome Aberrations (Chromosome Abnormalities) 12/2013 - 01/2010
2	Hypoalbuminemia 11/2012 - 03/2011
1	Residual Neoplasm 02/2024
1	Syncope (Fainting) 01/2023
1	Pneumonia (Pneumonitis) 01/2023
1	Hypertension (High Blood Pressure) 01/2023
1	COVID-19 01/2023
1	Thrombocytosis (Thrombocythemia) 01/2022
1	Leukopenia 10/2021
1	Hematologic Neoplasms (Hematological Malignancy) 01/2021
1	Mycoses (Diseases, Fungus) 01/2020
1	Hypoxia (Hypoxemia) 01/2020
1	Hyperglycemia 01/2020

Drug/Important Bio-Agent (IBA)

16	Lenalidomide (CC 5013)FDA Link 01/2023 - 01/2010
14	Azacitidine (5 Azacytidine)FDA Link 10/2021 - 05/2013
11	ruxolitinibIBA 10/2022 - 12/2013
10	luspaterceptIBA 11/2023 - 01/2020
8	HematinicsIBA 04/2024 - 01/2010
5	Phosphotransferases (Kinase)IBA 05/2024 - 03/2013
5	imetelstatIBA 04/2024 - 10/2021
5	Janus Kinase InhibitorsIBA 10/2022 - 12/2013
4	Telomerase (Telomerase Reverse Transcriptase)IBA 04/2024 - 10/2021
4	venetoclaxIBA 02/2024 - 01/2022
4	Biomarkers (Surrogate Marker)IBA 10/2021 - 11/2012
4	11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaeneIBA 01/2016 - 06/2014
3	Epoetin Alfa (Epogen)FDA Link 01/2023 - 10/2012
3	eltrombopag FDA Link 01/2020 - 01/2016
3	Imatinib Mesylate (Gleevec)FDA Link 12/2017 - 12/2008
3	Decitabine FDA Link 01/2017 - 09/2014
3	Serum AlbuminIBA 01/2017 - 03/2011
2	Proteins (Proteins, Gene)FDA Link 05/2024 - 01/2019
2	Hydroxyurea (Hydrea)FDA LinkGeneric 10/2022 - 12/2017
2	Hemoglobins (Hemoglobin)IBA 01/2022 - 01/2021
2	Erythropoietin FDA Link 01/2021 - 10/2012
2	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2020 - 07/2014
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2020 - 06/2013
2	IronIBA 01/2018 - 09/2017
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2016 - 11/2015
2	Cytarabine (Cytosar-U)FDA LinkGeneric 04/2014 - 12/2008
2	Cladribine FDA LinkGeneric 04/2014 - 12/2008
2	CytokinesIBA 06/2013 - 10/2012
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 06/2013 - 12/2008
1	AlarminsIBA 05/2024
1	Core Binding Factors (Core-Binding Factor)IBA 12/2023
1	DNA (Deoxyribonucleic Acid)IBA 05/2023
1	OligonucleotidesIBA 01/2023
1	Cytokine Receptors (Cytokine Receptor)IBA 11/2022
1	RNA (Ribonucleic Acid)IBA 11/2022
1	BI 836858IBA 11/2022
1	TESIBA 10/2022
1	RNA Splicing FactorsIBA 01/2022
1	navitoclaxIBA 01/2022
1	H3B-8800IBA 12/2021
1	MDS 11IBA 10/2021
1	eprenetapoptIBA 10/2021
1	Erythropoietin Receptors (Erythropoietin Receptor)IBA 01/2021
1	MucinsIBA 01/2021
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2020
1	Cytochrome P-450 CYP2C19IBA 01/2020
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2020
1	Voriconazole (Vfend)FDA LinkGeneric 01/2020
1	lenzilumabIBA 01/2020
1	Alanine Transaminase (SGPT)IBA 01/2020

Therapy/Procedure

39	Therapeutics 12/2023 - 12/2008
8	Erythrocyte Transfusion 04/2024 - 05/2016
8	Drug Therapy (Chemotherapy) 01/2019 - 12/2004
4	Hematopoietic Stem Cell Transplantation 01/2023 - 07/2005
4	Cell Transplantation 01/2022 - 11/2010
3	Stem Cell Transplantation 12/2018 - 12/2004
3	Induction Chemotherapy 01/2018 - 04/2011
2	Chelation Therapy (Therapy, Chelation) 01/2018 - 09/2017
1	Intravenous Infusions 12/2023
1	Transplantation 01/2023
1	Homologous Transplantation 01/2022
1	Immunotherapy 01/2021